-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
ZTS delivered challenging Q1 2026 results with adjusted EPS of $1.53 (+9% Y/Y) missing the consensus view of $1.62, while revenue of $2.262B (+3% Y/Y) met expectations. Performance reflected divergent regional dynamics, with International segment growth of 17% Y/Y ($1.149B) offsetting an 8% Y/Y decline in the U.S. segment ($1.090B). The company faced intensified competitive pressure in key dermatology franchises and heightened macroeconomic headwinds affecting U.S. pet owners, leading to reduced veterinary visits and softer demand for premium products. Management revised full-year 2026 guidance to $9.680B-$9.960B for revenue (2%-5% organic operational growth) and adjusted EPS of $6.85-$7.00, acknowledging current market pressures. We believe ZTS could be well-positioned for long-term growth with its portfolio breadth, robust pipeline of potential blockbusters, and proven innovation capabilities as key competitive advantages if it successfully navigates near-term headwinds.